Thoratec (Nasdaq: THOR) reported earnings on Aug. 1. Here are the numbers you need to know.

The 10-second takeaway
 For the quarter ended June 30 (Q2), Thoratec met expectations on revenues and met expectations on earnings per share.

Compared to the prior-year quarter, revenue expanded and GAAP earnings per share contracted.

Margins shrank across the board.

Revenue details
 Thoratec booked revenue of $118.7 million. The 18 analysts polled by S&P Capital IQ anticipated a top line of $120.4 million on the same basis. GAAP reported sales were 6.7% higher than the prior-year quarter's $111.2 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 EPS came in at $0.45. The 17 earnings estimates compiled by S&P Capital IQ predicted $0.45 per share. GAAP EPS of $0.35 for Q2 were 2.8% lower than the prior-year quarter's $0.36 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
 For the quarter, gross margin was 69.9%, 100 basis points worse than the prior-year quarter. Operating margin was 26.2%, 590 basis points worse than the prior-year quarter. Net margin was 17.5%, 210 basis points worse than the prior-year quarter.

Looking ahead
 Next quarter's average estimate for revenue is $111.4 million. On the bottom line, the average EPS estimate is $0.39.

Next year's average estimate for revenue is $469.1 million. The average EPS estimate is $1.73.

Investor sentiment
 The stock has a four-star rating (out of five) at Motley Fool CAPS, with 147 members out of 167 rating the stock outperform, and 20 members rating it underperform. Among 45 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 40 give Thoratec a green thumbs-up, and five give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Thoratec is outperform, with an average price target of $39.71.